Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 544
1953 833
1954 546
1955 407
1956 393
1957 388
1958 286
1959 232
1960 261
1961 235
1962 253
1963 510
1964 559
1965 293
1966 236
1967 375
1968 390
1969 372
1970 410
1971 327
1972 354
1973 378
1974 366
1975 249
1976 270
1977 229
1978 241
1979 231
1980 225
1981 194
1982 176
1983 174
1984 166
1985 206
1986 168
1987 140
1988 133
1989 162
1990 162
1991 164
1992 151
1993 175
1994 157
1995 171
1996 206
1997 180
1998 215
1999 180
2000 182
2001 182
2002 191
2003 202
2004 217
2005 210
2006 214
2007 245
2008 238
2009 239
2010 276
2011 333
2012 334
2013 315
2014 344
2015 368
2016 335
2017 378
2018 335
2019 193
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

18,572 results
Results by year
Filters applied: . Clear all
Page 1
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.
Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, Obeng Baah J, Marks GB, Long R, Hoeppner V, Elwood K, Al-Jahdali H, Gninafon M, Apriani L, Koesoemadinata RC, Kritski A, Rolla V, Bah B, Camara A, Boakye I, Cook VJ, Goldberg H, Valiquette C, Hornby K, Dion MJ, Li PZ, Hill PC, Schwartzman K, Benedetti A. Menzies D, et al. N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283. N Engl J Med. 2018. PMID: 30067931 Free article. Clinical Trial.
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. Swindells S, et al. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. N Engl J Med. 2019. PMID: 30865794 Free PMC article. Clinical Trial.
Safety and Side Effects of Rifampin versus Isoniazid in Children.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, Marks GB, Long R, Elwood K, Zielinski D, Gninafon M, Wulandari DA, Apriani L, Valiquette C, Fregonese F, Hornby K, Li PZ, Hill PC, Schwartzman K, Benedetti A, Menzies D. Diallo T, et al. N Engl J Med. 2018 Aug 2;379(5):454-463. doi: 10.1056/NEJMoa1714284. N Engl J Med. 2018. PMID: 30067928 Free article. Clinical Trial.
Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis.
Flentie K, Harrison GA, Tükenmez H, Livny J, Good JAD, Sarkar S, Zhu DX, Kinsella RL, Weiss LA, Solomon SD, Schene ME, Hansen MR, Cairns AG, Kulén M, Wixe T, Lindgren AEG, Chorell E, Bengtsson C, Krishnan KS, Hultgren SJ, Larsson C, Almqvist F, Stallings CL. Flentie K, et al. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10510-10517. doi: 10.1073/pnas.1818009116. Epub 2019 May 6. Proc Natl Acad Sci U S A. 2019. PMID: 31061116 Free PMC article.
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
Cornejo Garcia JG, Alarcón Guizado VA, Mendoza Ticona A, Alarcon E, Heldal E, Moore DAJ. Cornejo Garcia JG, et al. PLoS One. 2018 Dec 4;13(12):e0206658. doi: 10.1371/journal.pone.0206658. eCollection 2018. PLoS One. 2018. PMID: 30513085 Free PMC article. Clinical Trial.
Isoniazid mono-resistant tuberculosis: Time to take it seriously.
Garg K, Saini V, Dhillon R, Agarwal P. Garg K, et al. Indian J Tuberc. 2019 Apr;66(2):247-252. doi: 10.1016/j.ijtb.2019.04.001. Epub 2019 Apr 9. Indian J Tuberc. 2019. PMID: 31151492
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
CRyPTIC Consortium and the 100,000 Genomes Project, Allix-Béguec C, Arandjelovic I, Bi L, Beckert P, Bonnet M, Bradley P, Cabibbe AM, Cancino-Muñoz I, Caulfield MJ, Chaiprasert A, Cirillo DM, Clifton DA, Comas I, Crook DW, De Filippo MR, de Neeling H, Diel R, Drobniewski FA, Faksri K, Farhat MR, Fleming J, Fowler P, Fowler TA, Gao Q, Gardy J, Gascoyne-Binzi D, Gibertoni-Cruz AL, Gil-Brusola A, Golubchik T, Gonzalo X, Grandjean L, He G, Guthrie JL, Hoosdally S, Hunt M, Iqbal Z, Ismail N, Johnston J, Khanzada FM, Khor CC, Kohl TA, Kong C, Lipworth S, Liu Q, Maphalala G, Martinez E, Mathys V, Merker M, Miotto P, Mistry N, Moore DAJ, Murray M, Niemann S, Omar SV, Ong RT, Peto TEA, Posey JE, Prammananan T, Pym A, Rodrigues C, Rodrigues M, Rodwell T, Rossolini GM, Sánchez Padilla E, Schito M, Shen X, Shendure J, Sintchenko V, Sloutsky A, Smith EG, Snyder M, Soetaert K, Starks AM, Supply P, Suriyapol P, Tahseen S, Tang P, Teo YY, Thuong TNT, Thwaites G, Tortoli E, van Soolingen D, Walker AS, Walker TM, Wilcox M, Wilson DJ, Wyllie D, Yang Y, Zhang H, Zhao Y, Zhu B. CRyPTIC Consortium and the 100,000 Genomes Project, et al. N Engl J Med. 2018 Oct 11;379(15):1403-1415. doi: 10.1056/NEJMoa1800474. Epub 2018 Sep 26. N Engl J Med. 2018. PMID: 30280646 Free PMC article. Clinical Trial.
18,572 results
Jump to page
Feedback